BeiGene, Ltd.
BCL-2 INHIBITORS
Last updated:
Abstract:
Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same. ##STR00001##
Status:
Application
Type:
Utility
Filling date:
29 Apr 2019
Issue date:
2 Sep 2021